

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 3

COMPLETE IF KNOWN			
Application Number	10/510,881		
Filing Date	April 21, 2005		
First Named Inventor	KIPRIYANOV, et al.		
Art Unit	1646		
Examiner Name	Unassigned		
Attorney Docket Number	4121-172		

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Trans YES	lation NO ¹
/M.N./	AA	WO 00/29431	05-25-2000	Tanox, Inc.	х	
						
			· - 		!	
					 	
				· · · · · · · · · · · · · · · · · · ·		
	·			45.4	ļ	<u></u>
					.	
	<u> </u>		<u> </u>			
					}	
			1			
			- 			

	Examiner signature	/Meera Natarajan/	Date Considered 08/09/2007	
--	--------------------	-------------------	----------------------------	--

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

JUN 1 0 2005 %

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 3

COMPLETE IF KNOWN		
Application Number	10/510,881	
Filing Date	April 21, 2005	
First Named Inventor	KIPRIYANOV, et al.	
Art Unit	1646	
Examiner Name	Unassigned	
Attorney Docket Number	4121-172	

		NON-PATENT LITERATURE DOCUME	NTS		
Examiner Initials*	Cite No.	(
/M.N./	AB	Adams, Gregory P., et al., Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies, Cancer Research, vol 58, 1998, pp. 485-490.			
	AC	Arndt, Michaela A.E., et al., A Bispecific Diabody that Mediat Against Xenotransplanted Human Hodgkin's Tumors, Blood, v			
	AD				·
	AE				
	AF	Cochlovius, Björn, et al., Treatment of Human B Cell Lymphoma Xenografts with a CD3 x CD19 Diabody and T Cells, The Journal of Immunology, 2000, pp. 888-895.			
	AG	G da Costa, Ligia, et al., Immune Recruitment by Bispecific Antibodies for the Treatment of Hodgkin Disease, Cancer Chemother Pharmacol, vol 46, 2000, (Suppl), S33-S36.			
	АН				
	ΑI	Hartman, Standish C., et al., Two Dominant-Acting Selectable Markers for Gene Transfer Studies in Mammalian Cells, Proc. Natl. Acad. Sci. vol 85, 1988, pp. 8047-8051.			
	AJ	Kipriyanov, Sergey, et al., Bispecific CD3x CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells, Int. J. Cancer vol 77, 1998, pp. 763-772.			
V	AK	Kipriyanov, Sergey, et al., Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics, J. Mol. Biol. vol 293, 1999, pp. 41-56.			
/M.N./	AL	· · · · · · · · · · · · · · · · · · ·			
Examiner signature	Date 08/09/2007			08/09/2007	

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

JUH 1 0 2005 E

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 3 of 3

COMPLETE IF KNOWN		
Application Number	10/510,881	
Filing Date	April 21, 2005	
First Named Inventor	KIPRIYANOV, et al.	
Art Unit	1646	
Examiner Name	Unassigned	
Attorney Docket Number	4121-172	

Examiner	Cite	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title	
Initials*	No.	of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
/M.N./	AM	Kipriyanov, Sergey, et al., Novel Recombinant Bispecific Molecules for Immunotherapy of Blood Malignancies, Int. J. Cancer vol 77, 2001, pp. 763-772.	
	AN	Kudo, Toshio, et al., Specific Targeting Immunotherapy of Cancer with Bispecific Antibodies, <u>J.</u> Exp. Med., vol. 188, 1999, 275-288.	
	AO	Logan, John, et al., Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late after Infection, Proc. Natl. Acad. Sci. vol 81, 1984, 3655-3659.	
	AP	Lowy, Israel, et al., Isolation of Transforming DNA: Cloning the Hamster aprt Gene, Cell vol 22, 1980, 817-823.	·
	AQ	Matzinger, Polly, The JAM Test: A Simple Assay for DNA Fragmentation and Cell Death, Journal of Immunological Methods vol 145, 1991, 185-192.	
	AR	Pezzutto, Antonio, et al., CD19 Monoclonal Antibody HD37 Inhibits Anti-Immunoglobulin-Induced B Cell Activation and Proliferation, Journal of Immunology vol 138, 1987, 2793-2799.	
	AS	Renner, Christoph, et al., Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells, Science vol 264, 1994, 833-835.	
	ΑT	Wigler, Michael, et al., Transer of Purisied Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells, Cell vol 11, 1977, 223-232.	
V	AU	Wigler, Michael, et al., Transformation of Mammalian Cells with an Amplifiable Dominant- Acting Gene, Proc. Natl. Acad. Sci. vol 77, 1980, 3567-3570.	
/M.N./	AV	Zimmerman, Lyle, et al., Independent Regulatory Elements in the Nestin Gene Direct Transgene Expression to Neural Stem Cells or Muscle Precursors, Neuron vol 12, 1994, 11-24.	
			L

Examiner	INA. and Makanalan I	Date	
signature	/Meera Natarajan/	Considered	08/09/2007

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).